Production and clinical development of nanoparticles for gene delivery

Purpose: Gene therapy is a promising strategy for treating gene-associated diseases, but clinical application is limited by inefficient delivery. Naked nucleic acids suffer from nuclease degradation, rapid renal clearance, phagocyte uptake, poor target-cell uptake, and immune-related toxicity. Nanoparticles are considered the most promising vehicles for clinical gene therapy because their size, shape, surface, and biological behaviour can be tuned, but safe, efficient, and controllable nanoparticle delivery remains a bottleneck.

Hypothesis: No formal experimental hypothesis. Central thesis: nanoparticle-based delivery systems—lipid-, polymer-, and inorganic-based—can overcome delivery barriers and are progressing toward clinical gene therapy, but none had been FDA-approved at the time of writing; clinical translation depends on improving biodegradation, biocompatibility, targeting, cellular internalisation, endosomal escape, and safety.

Aims: Highlight the clinical development of nanoparticles for gene delivery. - Briefly review promising candidates closest to clinical application. - Summarise recent developments of nanoparticles for gene therapy in clinical trials. - Prospect future development of nanoparticles for clinical gene delivery.

Delivery system: Polymer-based nanoparticles: PLGA, chitosan, cyclodextrin-containing polycations (CDP), polyethyleneimine (PEI), PEG-PEI-cholesterol, poly(β-amino esters), polyphosphoesters, disulfide cross-linked polymers, PAMAM dendrimers, polypeptide-based cationic polymers. - Lipid-based nanoparticles: cationic liposomes, lipid nanoparticles, DMRIE-DOPE, DOTAP-cholesterol, lipopolyplexes, stable nucleic acid-lipid particles. - Inorganic nanoparticles: gold nanoparticles, magnetic nanoparticles. - Payloads: plasmid DNA, siRNA, mRNA, miRNA, antisense oligonucleotides. - Targeting/modifications: PEGylation, transferrin targeting, RGD peptide, hyaluronic acid coating, cell-penetrating peptides, endosomolytic agents, nuclear localisation signals, pH/light/redox-responsive systems. - Clinical candidates discussed: CALAA-01, ALN-VSP, ALN-TTR02, Allovectin-7, SGT-53, EGEN-001, BC-819/PEI, DTA-H19, TKM-080301, Atu027, DCR-MYC, ND-L02-s0201, siG12D LODER.

Approach: Review of preclinical and clinical literature; no primary experiments. Discusses first human gene therapy trial (ADA-SCID, 1990), SCID-X1 trial (2000) and subsequent leukaemia cases (2003), and nanoparticle clinical trials from phase 1 to phase 3. Disease contexts include cancers (ovarian, pancreatic, liver, lung, multiple myeloma, neuroendocrine tumours, solid tumours), transthyretin amyloidosis, hypercholesterolemia, optic atrophy, dry eye, and genetic immunodeficiency. Administration routes include systemic, intraperitoneal, intra-arterial, and local.

Key methods: Review-level synthesis of: - Nanoparticle characterisation: size, surface charge, PEGylation, stability, encapsulation. - Delivery barriers: biodegradation, biocompatibility, aggregation, nonspecific adsorption, extravasation, cellular internalisation, endosomal escape. - Clinical trial endpoints: safety, tolerability, pharmacokinetics, pharmacodynamics, target gene knockdown, tumour regression, survival. - Targeting strategies: passive EPR effect, active ligand-receptor targeting, stimulus-responsive delivery. - Combination approaches: gene therapy with chemotherapy, radiotherapy, photodynamic therapy, immunotherapy.

Key results: CALAA-01: first targeted nanoparticle-based siRNA delivery system in a phase 1 clinical trial; consisted of siRNA targeting RRM2, cyclodextrin-containing polymer, PEG, and transferrin targeting ligand; delivered siRNA systemically and showed antiproliferative activity across cancer cell types. - ALN-TTR02: lipid-based siRNA formulation for TTR amyloidosis; achieved up to 94% knockdown of serum TTR protein, sustained for 1 month; no infusion reactions at 0.3 mg/kg in phase 2. - ALN-VSP: lipid nanoparticle encapsulating VEGF siRNAs; systemic therapy induced regression of liver metastases and improved potential sensitivity to chemotherapy. - Allovectin-7: DMRIE-DOPE plus plasmid DNA; passed phase 2 but failed phase 3 for advanced metastatic melanoma and development was abandoned. - SGT-53: cationic liposome with anti-transferrin receptor single-chain antibody fragment and wtp53 plasmid; phase 2 with temozolomide for recurrent glioblastoma. - EGEN-001: IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer; phase 1 with carboplatin/docetaxel completed; phase 1 with pegylated liposomal doxorubicin recruiting. - PEI-based nanoparticles: several local clinical gene therapy trials for cancers, but substantial cytotoxicity limits further application. - No nanoparticle-based gene therapeutic had received FDA approval at the time of writing.

Interpretation: Nanoparticle-based gene delivery systems show potential for clinical gene therapy, with many candidates in clinical trials. However, none had achieved FDA approval. The primary obstacles include disease complexity, incomplete understanding of pathogenesis, safety and effectiveness of delivery systems, and the complicated in vivo microenvironment. Local administration and immunotherapy-based gene delivery are expected to reach approval more easily; systemic DNA/RNA delivery remains hindered by cross-reactivity and side effects. Combination approaches with drugs, radiotherapy, photodynamic therapy, or immunotherapy are expected to be a major future focus.

Limitations: Review article; no primary data. - No nanoparticle-based gene therapeutic had received FDA approval at the time of writing. - Clinical translation limited by biodegradation, biocompatibility, aggregation in physiological fluids, nonspecific adsorption, inefficient extravasation, poor cellular internalisation, and endosomal escape. - Viral vectors, though efficient, carry safety concerns including leukaemia caused by retroviral integration near proto-oncogenes. - Most clinical trials used local administration; systemic application remains challenging. - Precise interpretation of disease pathogenesis is a prerequisite for effective clinical gene therapy. - Structure-function relationships, anatomical barriers, nucleic acid stability, immunoreactivity, and delivery routes remain major clinical challenges.